Janssen has also announced that it will continue to make available branded Risperdal, which was first approved by the FDA in 1993.
Janssen’s Risperdal (risperidone) is indicated for the treatment of schizophrenia in adults and adolescents aged 13-17 years; and the treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years.